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ABSTRACT  
Background: Genomic data from HER2+ tumors were analyzed to assess the association 
between intrinsic subtype and clinical outcome in a large, well-annotated patient cohort. 
Methods: Samples from the NCCTG (Alliance) N9831 trial were analyzed using the Prosigna™ 
algorithm on the NanoString® platform to define intrinsic subtype, Risk of Recurrence scores, 
and Risk categories for 1392 HER2+ tumors. Subtypes were evaluated for recurrence-free 
survival (RFS) using Kaplan-Meier and Cox model analysis following adjuvant chemotherapy 
(n=484) or chemotherapy plus trastuzumab (n=908). All statistical tests were two-sided.  
Results: Patients with HER2+ tumors from N9831 were primarily scored as HER2-enriched 
(72.1%) These individuals received statistically significant benefit from trastuzumab (HR=0.68, 
95%CI=0.52-0.89, p=0.005), as did the patients (291/1392) with Luminal-type tumors (HR=0.52, 
95%CI=0.32-0.85, p=0.01). Patients with Basal-like tumors (97/1392) did not have statistically 
significantly better RFS when treated with trastuzumab and chemotherapy compared to 
chemotherapy alone (HR=1.06, 95%CI=0.53-2.13, p=0.87).  
Conclusions: The majority of clinically-defined HER2-positive tumors were classified as HER2-
enriched or Luminal using the Prosigna algorithm. Intrinsic subtype alone cannot replace 
conventional histopathological evaluation of HER2 status, since many tumors that are classified 
as Luminal A or Luminal B will benefit from adjuvant trastuzumab if that subtype is accompanied 
by HER2 overexpression. However, among tumors that overexpress HER2, we speculate that 
assessment of intrinsic subtype may influence treatment, particularly with respect to evaluating 
alternative therapeutic approaches for that subset of HER2-positive tumors of the Basal-like 
subtype. 
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INTRODUCTION 
With the advent of high dimensional technologies for quantifying expression of large numbers of 
genes, it has become clear that breast tumors exhibit a considerable range of 
molecular/genomic heterogeneity, both between and among the clinically defined cohorts of 
hormone receptor-positive, HER2-positive, and triple negative tumors. The most thoroughly 
characterized classifier of molecular heterogeneity is the PAM50 signature [1, 2] which uses the 
expression of 50 genes to stratify breast tumors into four major classes: Basal-like, HER2-
enriched, Luminal A, and Luminal B. There is a strong presupposition that these biological 
processes will prove to be informative of clinical/pathological features of breast tumors [2-6]. 
Our studies have focused upon defining molecular heterogeneity among HER2-positive 
(HER2+) breast tumors. We used the NanoString® Prosigna™ algorithm and PAM50 genes to 
define intrinsic subtypes and assess their distribution and association with outcome within 
tumors from the North Central Cancer Treatment Group [NCCTG (Alliance)] N9831 trial of 
patients with early stage HER2+ tumors [7, 8], randomized to receive adjuvant chemotherapy or 
chemotherapy plus trastuzumab. Our primary analytical focus was to test the hypothesis that 
benefit from adjuvant chemotherapy combined with trastuzumab, compared to benefit from 
adjuvant chemotherapy alone, varies as a function of intrinsic subtype.  
    
  MATERIALS AND METHODS  
Patients 
The NCCTG (Alliance) N9831 trial enrolled 3505 patients who were randomized to 3 study 
arms: Arm A - chemotherapy (doxorubicin and cyclophosphamide followed by weekly 
paclitaxel); Arm B - chemotherapy followed by 52 weeks of weekly trastuzumab; and Arm C - 
5 
 
chemotherapy with 12 weeks of trastuzumab concurrent with paclitaxel followed by 40 more 
weeks of weekly trastuzumab alone, as previously described in detail [7]. Patients in both 
trastuzumab-treated arms (B and C) received 52wk of trastuzumab and showed statistically 
significant improvement in relapse-free survival [7, 8], compared to patients who received 
chemotherapy alone (Arm A). We therefore combined patients from Arms B and C into a single 
trastuzumab-treated group (Arm B/C) for subsequent analysis.  All patients included in this 
analysis were assessed for central HER2 IHC and/or FISH as part of the N9831 parent study, 
as previously described [7]. Informed written consent to these studies was obtained from all 
patients. Studies were carried out under Mayo Clinic Institutional Review Board protocols 954-
00 and 13-000290. 
Statistical Analysis 
The main objective of the analysis was to determine whether the effect of trastuzumab 
qualitatively differed for any of the intrinsic subtypes. If differing treatment effects were observed 
among the subtypes, a test for interaction was to be performed to determined whether this 
observation was statistically significant. The primary endpoint for outcome analysis was 
recurrence-free survival (RFS), defined as the time from randomization to breast cancer 
recurrence (local, regional, or distant recurrence of breast cancer or breast cancer related 
death). The time to event for patients who died without recurrence was considered censored at 
the time of death.  Cox proportional hazard models were used to generate point estimates of 
hazard ratios (HRs) and corresponding 95% confidence intervals (95%CI) to assess the benefit 
of trastuzumab for RFS comparisons. The assumption of proportional hazards was verified with 
a Cox proportional hazard model containing the treatment indicator and the interaction of the 
indicator with the log of time. The test of proportionality involves a likelihood ratio test of the 
model containing the interaction term against the model that contains the treatment variable 
only. A non-significant p-value of this test suggests there is not sufficient evidence to reject the 
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assumption of proportional hazards. The p-value of this test was 0.88, suggesting that there is 
not sufficient evidence to reject the assumption of proportional hazards.Wald Chi-square p-
values were calculated for the Cox hazard ratios. Comparisons were made both within and 
between treatment arms. The interaction term of Basal-like vs Non-Basal-like by treatment arm 
was determined using a Cox model that also included the main effects; this interaction was 
tested because the effect of trastuzumab appeared qualitatively different in this subtype.  
Kaplan-Meier plots were used to depict the proportion of patients free from breast cancer 
recurrence as a function of time. Chi-square tests for nominal categories or Cochran-Mantel-
Haenszel tests for ordered categories were performed to ascertain differences in eligible N9831 
patients included in the analysis with those that were excluded. All statistical tests were two-
sided and a P value of less than 0.05 was considered statistically significant.  
Assignment of intrinsic subtype 
We constructed a NanoString® custom CodeSet that includes the PAM50 genes plus 
appropriate housekeeping genes (B2M, GAPDH, POLR2A, UBC, YWHAZ) for normalization 
purposes. The Prosigna™ subtyping algorithm is trained for use with Prosigna™ CodeSet.  To 
use this algorithm for subtyping N9831 data, adjustment factors that account for differences 
between the custom CodeSet used in the N9831 study and the Prosigna™ CodeSet were 
estimated and applied to the data. To this end, 30 samples, which were processed with the 
custom CodeSet, were re-processed using the Prosigna™ CodeSet.  For each probe, this 
provided 30 pairs of counts (corresponding to the two CodeSets), which were then used to 
estimate the adjustment factor between the two CodeSets. Specifically, for each of the PAM50 
probes, first, the ratio of the normalized counts from the custom CodeSet relative to their 
corresponding normalized counts from the Prosigna™ CodeSet were calculated, resulting in 30 
ratios for each of the probes. Then, for each probe, the median of the 30 ratios were taken as 
the adjustment factor.  Subsequently, the resultant 50 adjustment factors (one for each PAM50 
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gene) were applied to the PAM50 counts in the original dataset and subtyping was performed 
on the adjusted counts per standard Prosigna™ algorithm. Quantitative real time PCR data on 
mRNA abundance, proliferative scores, and mitotic indices were abstracted from a published 
study on the OncotypeDX analysis of N9831 samples9. 
 
RESULTS 
Assignment of risk scores and intrinsic subtype using Prosigna™ 
Samples from 1426 eligible patients had sufficient RNA for testing and were analyzed on the 
NanoString® platform to measure the abundance of mRNAs that define the intrinsic subtype 
patterns. Thirty four samples were excluded for quality control issues, mostly low total gene 
counts; 1392 remaining samples (Arm A: 484, Arm B: 494, Arm C: 414) were analyzed for 
intrinsic subtype in a blinded fashion. Patient demographics for samples that were included as 
well as those from whom RNA was not available are given in Supplementary Table 1. 
Distributions of intrinsic subtypes, Risk of Recurrence scores (ROR), and Risk 
categories (High, Intermediate, Low) as a function of treatment arm are given in Table 1, and 
clinical/pathological features of the tumors by treatment are in Supplementary Table 2. There 
were small, but statistically significant differences in nodal status between the two arms 
(p=0.04). However, the observed increase in node 0 and node 1-3 patients in Arm B/C did not 
translate into differences in Risk category (Table 1). 
The patients enrolled in N9831 were centrally confirmed as HER2+. The majority of the 
tumors (1004/1392, 72.1%) were classified by ProsignaTM as HER2-enriched. The remaining 
tumors were more or less equally distributed among the Basal-like (97/1392, 7.0%), Luminal A 
(132/1392, 9.5%), or Luminal B (159/1392, 11.4%) subtypes. 
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Association between risk of recurrence score, risk category, and RFS 
The Prosigna™ algorithm reports a risk of recurrence (ROR) score that combines intrinsic 
subtype, tumor size, and proliferation score into a single metric. The majority of the N9831 
samples (1045/1392) had ROR scores >70, where low risk is considered 1-40, intermediate risk 
40-60, and high risk >60. We did not observe a statistically significant association between RFS 
and ROR, expressed as a discontinuous, quantile score, among patients who received 
chemotherapy alone (Arm A, Figure 1A, p=0.40) or patients who received chemotherapy plus 
trastuzumab (Arms B/C, Figure 1B, p=0.37).  
Tumor size is incorporated into ROR to stratify tumors into High, Intermediate, and Low 
Risk categories. Almost all of the N9831 samples were classified as High Risk (1335/1392, 
Table 1). The Kaplan-Meier analysis suggested a quantitative tendency towards improved RFS 
in the few Low/Intermediate Risk patients who received chemotherapy alone; however, this 
tendency did not achieve statistical significance (Arm A, Figure 1C, p=0.13). Low/Intermediate 
Risk patients who received trastuzumab appeared to receive statistically significant benefit (Arm 
B/C, Figure 1D p=0.01). Among the tumors with Low/Intermediate Risk, those classified as 
estrogen receptor and/or progesterone receptor-positive seldom recurred. Among 30 such 
patients, only 1 recurrence was reported, compared to the overall recurrence rate of about 1 in 4 
(317/1392) for all patients in this study (Chi Square p=0.01).  
A subset of the N9831 patients (445 from Arm A and 397 from Arm C) has previously 
been analyzed using the 21 gene OncotypeDXTM panel9. As with the ProsignaTM analysis, 
almost all of the patients were classified as high risk (763/842). A number of molecular features 
associated with subtype were derived from the 21 gene signature, including ERBB2 mRNA, 
proliferative score, and Ki67 mRNA. Percent cells staining 3+ for HER2 was extracted from the 
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clinical record, and mitotic index was assessed by histological examination, as shown in Table 
2. The proliferative markers associated with each subtype were ranked Basal-like>HER2-
enriched≈Luminal B>Luminal A. HER2 expression generally followed the pattern HER2-
enriched>Luminal A>Luminal B≈>Basal-like. Among the four subtypes, the Basal-like tumors 
exhibited the lowest HER2 expression and the highest proliferation, features that might be 
expected to influence outcome following HER2-targeted therapy. 
 
Association between intrinsic subtype and RFS 
A statistically significant association between RFS and intrinsic subtype was observed when all 
patients (irrespective of therapy) were evaluated (Figure 2A). Patients with Basal-like tumors 
exhibited statistically significantly worse RFS compared to patients with HER2-enriched, 
Luminal A, or Luminal B subtypes. When intrinsic subtype was evaluated within each treatment 
arm, there was no statistically significant association between subtype and RFS in the patients 
who received chemotherapy alone (Figure 2B, log rank p=0.79; HRBasal=reference; 
HRHER2=0.75, 95%CI=0.42-1.33, p=0.32; HRLumA=0.76, 95% CI=0.35-1.64, p=0.32; 
HRLumB=0.83, 95%CI=0.41-1.69, p=0.61). However, a statistically significant association was 
observed between outcome and intrinsic subtype among patients who received trastuzumab 
(Figure 2C, log rank p=0.007; HRBasal=reference; HRHER2=0.49, 95%CI=0.30-0.78, p=0.003; 
HRLumA=0.47, 95%CI=0.25-0.90, p=0.02; HRLumB=0.35, 95%CI=0.18-0.68, p=0.002).  
RFS as a function of treatment and subtype  
The data in Figure 2 suggest that there is a relationship between intrinsic subtype and outcome 
and that this relationship resides primarily in those patients who received adjuvant trastuzumab. 
We therefore evaluated the relationship between RFS and treatment within each subtype. 
Trastuzumab appeared to have little or no statistically significant association with RFS in 
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HER2+ patients of the Basal-like subtype (Figure 3A, HR=1.06, 95%CI=0.53-2.13, p=0.87). 
Patients with HER2-enriched genomic profiles received statistically significant benefit from 
trastuzumab, compared to chemotherapy alone (Figure 3B, HR=0.68. 95%CI=0.52-0.89, 
p=0.005). Patients with Luminal A profiles exhibited a quantitative trend towards improved RFS, 
although this trend did not achieve statistical significance (blue curve vs green curve in Figure 
3C, HR=0.62, 95%CI=0.30-1.26, p=0.20). HER2+ tumors with Luminal B profiles benefitted 
statistically significantly (red curve vs brown curve in Figure 3C, HR=0.45, 95%CI=0.22-0.88, 
p=0.02). Due to the small number of events in patients with Luminal-type tumors, we combined 
the Luminal A and B tumors into a single cohort of Luminal-type tumors for subsequent 
analyses. Trastuzumab provided statistically significant benefit in patients whose tumors 
exhibited Luminal profiles (Figure 3D, HR=0.52, 95%CI=0.32-0.85, p=0.01).  
A Cox model was used to evaluate RFS among Basal and Non-Basal tumors. The HRs 
for RFS of Basal-like tumors in Arm A did not appear to be statistically significantly different from 
those of Non-Basal tumors after chemotherapy (Table 3A, Arm A Basal-like vs Arm A Non-
Basal, HR=0.76, 95%CI=0.43-1.34, p=0.34). In addition, RFS was not statistically significantly 
different between Basal-like tumors after chemotherapy versus after chemotherapy plus 
trastuzumab (Table 3B, Arm A Basal-like vs Arm B/C Basal-like, HR=1.06, 95%CI=0.53-2.13, 
p=0.87). As expected, RFS among the Non-Basal cohort was statistically significantly improved 
by trastuzumab (Table 3B, Arm A Non-Basal vs Arm B/C Non-Basal, HR=0.65, 95%CI=0.51-
0.82, p<0.001). Moreover, RFS after trastuzumab was statistically significantly better among 
Non-Basal-like tumors (Table 3A, Arm B/C Basal-like vs Arm B/C Non-Basal-like, HR=0.47, 
95%CI=0.29-0.74, p=0.001). However, the test for interaction of treatment arm (A vs B/C) by 
tumor subtype (Basal vs Non-Basal) did not achieve statistical significance (p=0.20), which may 
or may not be due to the small number of Basal-like tumors in our sample cohort. 
Hormone receptor status and outcome among Non-Basal tumors  
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Since Basal-like tumors are generally estrogen receptor (ER) and/or progesterone receptor 
(PR)-negative, we evaluated the association between subtype, outcome, and ER/PR status. 
Patients with ER/PR-positive or ER/PR-negative non-Basal-like tumors had similar RFS after 
chemotherapy (Table 3C, Arm A ER/PR-neg vs Arm A ER/PR-pos, HR=0.90, 95%CI=0.63-
1.28, p=0.55). Likewise, ER/PR status was not statistically significantly associated with outcome 
after trastuzumab treatment of Non-Basal tumors (Table 3C, Arm B/C ER/PR-neg vs Arm B/C 
ER/PR-pos, HR=0.84, 95% CI=0.62-1.14, p=0.27). Moreover, both patients with ER/PR-positive 
and negative tumors with Non-Basal features appeared to benefit from trastuzumab (Arm A 
ER/PR-neg vs Arm B/C ER/PR-neg, HR=0.67, 95% CI=0.47-0.85, p=0.02; Arm A ER/PR-pos vs 
Arm B/C ER/PR-pos, HR=0.62, 95% CI=0.45-0.85, p=0.003).  
 
DISCUSSION 
Intrinsic subtype, defined by abundance of transcripts that correspond to the PAM50 cohort of 
genes, has gained wide acceptance as a tool for stratifying breast tumors based on the extent to 
which these tumors exhibit expression profiles that correspond to Basal-like, HER2-enriched, 
Luminal A, or Luminal B samples. All of the samples included in this analysis were centrally 
evaluated for HER2 protein or gene copy number at Mayo Clinic7. Thus, our data reflect 
molecular heterogeneity within clinically well-define HER2+ tumors, such that some HER2+ 
tumors exhibit Basal-like or Luminal gene expression profiles. These results are consistent with 
others published elsewhere10-12. Evaluation of several molecular features associated with 
subtype suggests that there are statistically significant differences in HER2 expression and 
proliferation. Most notably, the Basal-like tumors exhibited statistically significantly lower HER2 
mRNA and percent of cells staining 3+ for HER2, coupled with high proliferative markers. Both 
of these features might plausibly be associated with outcome.  
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To our knowledge, this is the first report of the use of the Prosigna™ algorithm to define 
intrinsic subtype distribution and outcome following adjuvant trastuzumab therapy of HER2+ 
tumors. Our data are broadly consistent with analyses of intrinsic subtype among HER2+ 
tumors from The Cancer Genome Atlas 10, the NOAH neoadjuvant 11, and the NSABP B31 
adjuvant trastuzumab trials 12, in which the research PAM50 algorithm was used to assess 
molecular heterogeneity among tumors that are clinically defined as HER2+. The key question 
is to what extent this molecular heterogeneity is associated with clinical outcome following 
trastuzumab. As reported in the NOAH and NSABP B31/PAM50 analysis we observed that 
HER2+ tumors with HER2-enriched profiles are generally responsive to trastuzumab. Thus, the 
HER2-enriched profile is predictive of better outcome following adjuvant trastuzumab. The data 
with the HER2+ Luminal subtypes are somewhat more difficult to evaluate. These patients tend 
to do very well and few events were recorded. We observed a qualitative trend towards 
increased RFS in trastuzumab-treated patients with both Luminal A and Luminal B tumors, 
although statistical significance was not achieved with the Luminal A subgroup.  Nevertheless, 
the data suggest that HER2+ patients whose tumors express Luminal signatures likely receive 
additional benefit from trastuzumab, above and beyond that received from chemotherapy alone.  
The majority of the HER2+ tumors were classified as high risk, by both ProsignaTM and 
OncotypeDXTM. It is unclear if the small subset of patients with Low/Intermediate Risk, estrogen 
and/or progesterone receptor-positive early stage HER2+ tumors require adjuvant trastuzumab. 
The number of such patients enrolled in N9831 was small.Additional studies will be required to 
assess the relationship between Risk category and RFS among patients with hormone-receptor 
positive tumors. 
The data indicate that Non-Basal HER2+ tumors (i.e., those tumors with HER2-enriched, 
Luminal A or Luminal B profiles) are responsive to trastuzumab, irrespective of hormone 
receptor status. A subset, about 7%, of HER2+ tumors in the N9831 study exhibited gene 
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expression profiles that resemble those of Basal-like tumors. Similar results were observed in 
analysis of 1711 samples from The Cancer Genome Atlas Network, 2012 #16062} and 
METABRIC databases (14.1% Basal-like)13 and 1579 samples from the NSABP B31 trial (6.5% 
Basal-like) 12.  The data presented here suggest that HER2+ tumors with Basal-like features 
may benefit less from adjuvant trastuzumab. This suggestion is consistent with the molecular 
features of these tumors, which express low levels of HER2 and appear to be highly 
proliferative. However, the conclusion that patients with such tumors will not benefit from 
trastuzumab is not warranted by the data. Although the hazard ratio for RFS following 
trastuzumab is not statistically significantly different from that observed with chemotherapy 
alone (HR=1.06, p=0.87), the 95% confidence intervals are very large (0.53 to 2.13), and the 
test for interaction between treatment and subtype (Basal vs Non-Basal) was not statistically 
significant. Moreover, Pogue-Geile et al. reported that Basal-like tumors in the NSABP B31 trial 
received statistically significant benefit from adjuvant trastuzumab 12. There are some 
differences in the algorithms used to call intrinsic subtype in our study and that reported by 
Pogue-Geile. They reported disease free survival, whereas we report breast cancer relapse free 
survival. Perhaps more importantly, they used a modified version of the PAM50 algorithm, 
rather than the ProsignaTM algorithm used in our studies. These two algorithms use different 
normalization strategies; and they called 47% of the HER2+ tumors in B31 as HER2-enriched, 
whereas we called 73% of the N9831 HER2+ samples as HER2-enriched. Furthermore, both 
studies were limited in power by the relative small number of Basal-like tumors that were 
identified. Given these considerations, we are inclined to the most conservative conclusion: that 
additional studies will be required to sort out the role of intrinsic subtype in predicting response 
to HER2-targeted therapy in the adjuvant setting.   
There are a couple of limitations of this study. The first is that it is a retrospective 
analysis of samples from less than half of the patient enrolled on N9831. This due to the fact 
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that the submission of patient samples was optional for this study and that some samples were 
dropped due to poor quality. It is recognized that this could bias the results. A comparison of 
patients with samples used in this analysis to patients not included in the analysis only showed 
some clinical-pathological differences (e.g. patients with larger tumors are included in this 
analysis), but there was no difference observed in the treatment effect between the patients 
included in this study and patients not included in this study. Another limitation is that some of 
the identified intrinsic subtype groups had a relatively small number of patients and events. This 
limits the power of the analyses in these subgroups, which makes statistically non-significant 
results hard to interpret: they could be reflective of no real difference between the groups or 
could be due to lack of power to detect a difference of interest. 
Finally, our data indicate that evaluation of HER2 status by IHC and/or FISH is an 
essential component of clinical management of breast cancer patients. Intrinsic subtype alone 
cannot replace conventional histopathological evaluation of HER2 status, since many tumors 
that are classified as Luminal A or Luminal B will benefit from adjuvant trastuzumab if that 
subtype is accompanied by HER2 overexpression. However, among tumors that overexpress 
HER2, we speculate that assessment of intrinsic subtype may guide further treatment 
development, particularly with respect to evaluating alternative therapeutic approaches for that 
subset of HER2+ tumors of the Basal-like subtype. Given the relative rarity of such tumors, 
additional studies will be required to evaluate this idea.     
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TABLES 
Table 1. Comparison of Prosigna intrinsic subtype, Risk of Recurrence (ROR), and Risk 
Category in Arm A (chemotherapy alone) and Arm B/C (chemotherapy plus trastuzumab) 
of N9831. 
Subtype Arm A Arm B/C p-value* 
Basal 38 (7.9%) 59 (6.5%) 0.76 
HER2 342 (70.7%) 662 (72.9%) 
Luminal A 47 (9.7%) 85 (9.4%) 
Luminal B 57 (11.7%) 102 (11.2%) 
ROR    
1. <70 140 (28.9%) 207 (22.8%) 0.03 
2. 70-81 116 (23.9%) 220 (24.2%) 
3. 82-91 108 (22.3%) 240 (26.4%) 
4. 92-100 120 (24.7%) 241 (26.5%) 
Risk category    
High 462 (95.4%) 873 (96.1%) 0.54 
Intermediate/Low 22 (4.5%) 35 (3.8%) 
* p-value from Chi-square test for nominal categories or Cochran-Mantel-Haenszel test for 
ordered categories.  
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Table 2: Basal-like HER2+ tumors exhibit lower ERBB2 expression and higher proliferation* 
Subtype 
ERBB2 
mRNA 
(95% CI) 
p-
value† 
% IHC 3+ 
cells 
(95%CI) 
p-
value† 
Proliferative 
score (95% 
CI) 
p-value† 
Ki67 mRNA 
(95% CI) 
p-value† 
Mitotic 
score (95% 
CI) 
p-value† 
Basal-like (n=56) 
10.8 
(11.3,10.4) 
ref 
49.2 
(61.9,36.5) 
ref 
6.91 
(7.03,6.78) 
ref 
7.93 
(8.07,7.79) 
ref 
2.55 
(2.74,2.36) 
ref 
HER2-enriched 
(n=607) 
13.0 
(13.1,12.9) 
<0.001 
91.2 
(92.9,89.4) 
<0.001 
6.52 
(6.56,6.48) 
<0.001 
7.50 
(7.55,7.45) 
<0.001 
2.01 
(2.08,1.94) 
<0.001 
Luminal A (n=75) 
11.7 
(12.0,11.4) 
0.002  
64.6 
(74.6,54.6) 
0.03  
5.78 
(5.90,5.65) 
<0.001 
6.79 
(695,6.62) 
<0.001 
1.37 
(1.52,1.22) 
<0.001 
Luminal B (n=104) 
11.1 
(11.4,10.6) 
0.11 
45.8 
(55.2,36.4) 
0.67 
6.56 
(6.68,6.44) 
<0.001 
7.49 
(7.61,7.37) 
<0.001 
1.56 
(1.71,1.40) 
<0.001 
Luminal All (n=179) 
11.4 
(11.6,11.2) 
0.01 
54.2 
(61.2,47.3) 
0.42 
6.23 
(6.34,6.13) 
<0.001 
7.20 
(7.30,7.09) 
<0.001 
1.48 
(1.60,1.37) 
<0.001 
*Data are summarized from 842 samples from Arm A (445) and Arm C (397 that were analyzed using the OncotypeDXTM 21 gene 
signature 9. Proliferative score is the average of 5 proliferative marker genes in this panel. Mitotic score was determined by 
histological examination by F. Baehner. All mRNA abundance data were normalized and scaled to log base 2. IHC staining for HER2 
abundance (%3+ cells) were extracted from the clinical record, as previously described. Abbreviations: % IHC 3+ = percent of 
tumor cells with membrane scoring 3+ by clinical pathology, Ki67=mRNA encoded by MKI67 
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† Mann-Whitney U test, two sided p-value for comparison to Basal-like tumors.  
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Table 3. HER2+ tumors with Basal-like signatures have different outcomes than HER2+ 
tumors with Non-Basal signature* 
Panel A: RFS as a function of subtype (Basal vs Non-Basal) by treatment arm 
Arm Subtype N Events(%) HR 95%CI p-value† 
A Basal-like 38 13 (34.2) 1.0   
A Non-Basal-like 446 123 (27.5) 0.76 0.43, 1.34 0.34 
B/C Basal-like 59 20 (33.8) 1.0   
B/C Non-Basal-like 849 161 (19.0) 0.47 0.29, 0.74 0.001 
Panel B: RFS as a function of treatment (Arm A vs Arm B/C) by subtype 
Arm Subtype N Events(%) HR 95%CI p-value† 
A Basal-like 38 13 (34.2) 1.0   
B/C Basal-like 59 20 (33.8) 1.06 0.53, 2.13 0.87 
A Non-Basal-like 446 123 (27.5) 1.0   
B/C Non-Basal-like 849 161 (19.0) 0.65 0.51, 0.82 <0.001 
Panel C: RFS by ER/PR status as a function of Arm within Non-Basal tumors 
Arm 
Hormone Receptor 
Status 
N Events(%) HR 95%CI p-value 
A ER/PR-negative 192 54 (28.1) 1.0   
A ER/PR-positive 254 69 (27.2) 0.90 0.63, 1.28 0.55 
B/C ER/PR-negative 381 76 (19.9) 1.0   
B/C ER/PR-positive 468 85 (18.2) 0.84 0.62, 1.14 0.27 
Panel D: RFS by treatment Arm and ER/PR status with Non-Basal tumors 
Arm 
Hormone Receptor 
Status 
N Events(%) HR 95%CI p-value† 
A ER/PR-negative 192 54 (28.1) 1.0   
B/C ER/PR-negative 381 76 (19.9) 0.67 0.47, 0.95 0.02 
A ER/PR-positive 254 69 (27.2) 1.0   
B/C ER/PR-positive 468 85 (18.2) 0.62 0.45, 0.85 0.003 
* Cox model analysis was carried out to compare RFS between Basal-like and Non-Basal 
tumors in Arm A or in Arm C (Panel A). In addition, the Cox model was used to compare 
outcome as a function of treatment (Arm A vs Arm B/C) as a function of Basal-like or Non-Basal 
subtype (Panel B). Test for interaction of Arm and Basal Subtype Status p=0.20. A Cox model 
analysis was used to define hazard ratio (HR) for recurrence as a function of ER/PR status and 
treatment (Panel C). Wald Chi-square p-values were calculated from the Cox model data. The 
effect of treatment (Arm A vs Arm B/C) is shown as a function of ER/PR status in Panel D. Test 
for interaction of Arm and HR Status p=0.79.  
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FIGURE LEGENDS 
Figure 1: Risk of Recurrence (ROR) scores and RISK categories among HER2+ tumors. 
The Prosigna algorithm reports two scores, ROR and RISK. The association between ROR 
scores and RFS after chemotherapy (Panel A) or chemotherapy plus trastuzumab (Panel B) 
are shown. The majority of the HER2+ tumors were assigned as High Risk. The association 
between RISK category and RFS after chemotherapy (Panel C) or chemotherapy plus 
trastuzumab (Panel D) are given. Kaplan-Meier log rank survival analysis (two-sided) was used 
to calculate p-values.  
Figure 2: Intrinsic subtype and relapse free survival among patients in the N9831 trial. 
The relationship between RFS and time, evaluated as a function of Prosigna subtype in all arms 
of the N9831 trial is shown in Panel A. The relationship between RFS and subtype in patients 
enrolled in Arm A, chemotherapy alone, in Panel B, whereas RFS as a function of subtype in 
patients enrolled in Arm B/C, chemotherapy plus trastuzumab, is given in Panel C.Kaplan-Meier 
log rank p-values (two sided) were calculated. The Cox model (two sided) was used to estimate 
hazard ratios.  
 
Figure 3: HER2+ tumors with Basal-like expression profiles compared to tumors with 
HER2-enriched or Luminal-type expression profiles. Relapse-free survival, plotted as 
Kaplan-Meier curves was compared for Arm A (chemotherapy alone) versus Arm B/C 
(chemotherapy plus trastuzumab) for N9831 tumors with Basal-like (Panel A) or HER2-enriched 
(Panel B) Prosignal subtype profiles. Log rank statistics were used to calculate p-values for 
RFS as a continuous variable. HRs on the basis of % RFS 10yr following randomization. 
Survival analysis was also carried out for Luminal A and Luminal B subtypes, individually (Panel 
C) and combined into a Luminal-type category (Panel D). All statistical tests were two-sided.  
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Supplemental Table 1: Patient and Tumor Characteristics: Comparison of 
Nanostring Cohort vs Eligible Patients Not Included in the Cohort. 
 
Characteristic 
Eligible  
But Not Included 
(n=1740) 
Nano-String Cohort 
(n=1392) 
p-value* 
Arm     
A 603 (34.6%) 484 (34.8%) 
0.80 B 602 (34.6%) 494 (35.5%) 
C 535 (30.7%) 414 (29.7%) 
Age at Randomization (years)    
18-39 304 (17.5%) 239 (17.2%) 
0.03 
40-49 609 (35.0%) 428 (30.7%) 
50-59 553 (31.8%) 467 (33.5%) 
≥60 274 (15.7%) 258 (18.5%) 
Race    
      Caucasian 1440 (82.8%) 1206 (86.6%) 0.003 
      Other 300 (17%) 186 (13%)  
Menopausal Status    
Premenopausal  965 (55.4%) 720 (51.7%) 
0.04 
Postmenopausal 775 (44.5%) 672 (48.3%) 
Extent of Surgery    
Breast sparing 671 (38.6%) 540 (38.8%) 
0.90 
Mastectomy 1069 (61.4%) 852 (61.2%) 
Extent of Nodal Examination    
Axillary node dissection 1556 (89.4%) 1266 (90.9%) 
0.16 
Sentinel biopsy 184 (10.6%) 126 (9.1%) 
Histologically Positive Nodes    
0 233 (13.4%) 183 (13.1%) 
0.15 
1-3 847 (48.7%) 638 (45.8%) 
4-9 440 (25.3%) 378 (27.2%) 
≥10 220 (12.6%) 193 (13.9%) 
Tumor Size (cm)    
≤ 2.0 722 (41.5%) 528 (37.9%) 
0.004 2.1 - 4.9 893 (51.3%) 723 (51.9%) 
≥5 125 (7.2%) 141 (10.1%) 
Tumor Grade    
Low/Intermediate 473 (27.2%) 380 (27.3%) 
0.95 High 1244 (71.5%) 994 (71.4%) 
Unknown 23 (1.6%) 18 (1.3%) 
Hormone Receptor Status    
     ER or PR Positive 954 (54.8%) 735 (52.8%) 0.26 
      Other 786 (45.2%) 657 (47.2%) 
Histology    
      Ductal 1641 (94.3%) 1321 (94.9%) 
0.50 
      Other 97 (5.6%) 70 (5.0%) 
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Characteristic 
Eligible  
But Not Included 
(n=1740) 
Nano-String Cohort 
(n=1392) 
p-value* 
Missing 2 (0.1%) 1 (0.1%)  
Hormonal Therapy    
      Yes 922 (53.0%) 705 (51%) 0.16 
      No 804 (46.2%) 681 (49%) 
Missing 14 (0.8%) 6 (0.4%) 
Agent    
Tamoxifen 627 (36.0%) 471 (33.8%) 0.32 
Other 295 (17.0%) 234 (16.8%) 
None 804 (46.2%) 681 (48.8%) 
Missing 14 (0.8%) 6 (0.4%) 
* p-value from Chi-square test for nominal categories or Cochran-Mantel-Haenszel test for ordered categories. 
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Supplemental Table 2: Patient and Tumor Characteristics Comparison by Arm. 
 
Characteristic 
Arm A  
(n=484) 
Arm B/C 
 (n=908) 
p-value* 
Age at Randomization (years)      
18-39 78 (16.1%) 161 (17.7%) 
0.89 
40-49 153 (31.6%) 275 (30.3%) 
50-59 167 (34.5%) 300 (33.0%) 
≥60 86 (18%) 172 (18.9%) 
Race      
      Caucasian 426 (88.6%) 780 (85.9%) 0.27 
      Other 58 (12%) 128 (14.1%)  
Menopausal Status      
Premenopausal  247 (51.0%) 473 (52.1%) 
0.71 
Postmenopausal 237 (49.0%) 435 (48.2%) 
Extent of Surgery      
Breast sparing 188 (38.8%) 352 (38.8%) 
0.98 
Mastectomy 296 (61.1%) 556 (61.2%) 
Extent of Nodal Examination      
Axillary node dissection 439 (90.7%) 827 (91.1%) 
0.82 
Sentinel biopsy 45 (9.2%) 81 (8.9%) 
Histologically Positive Nodes      
0 58 (12.0%) 125 (13.8%) 
0.04 
1-3 210 (43.4%) 428 (47.1%) 
4-9 140 (28.9%) 238 (26.2%) 
≥10 76 (15.7%) 117 (12.9%) 
Tumor Size (cm)      
≤ 2.0 192 (39.7%) 336 (37.0%) 
0.27 2.1 - 4.9 247 (51.0%) 476 (52.4%) 
≥5 45 (9.3%) 96 (10.6%) 
Tumor Grade    
Low/Intermediate 131 (27.1%) 249 (27.4%) 
0.93 High 345 (71.3%) 649 (71.4%) 
Unknown 8 10 
Hormone Receptor Status    
     ER or PR Positive 260 (53.7%) 475 (52.3%) 0.62 
      Other 224 (46.3%) 433 (47.7%) 
Histology    
      Ductal 459 (94.8%) 862 (94.9%) 
0.87       Other 25 (5.2%) 45 (4.9%) 
Missing 0 (0.0%) 1 (0.1%) 
Hormonal Therapy    
      Yes 247 (51.0%) 458 (51%) 0.75 
      No 233 (48.1%) 448 (49%) 
Missing 4 (0.8%) 2 (0.2%) 
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Characteristic 
Arm A  
(n=484) 
Arm B/C 
 (n=908) 
p-value* 
Agent    
Tamoxifen 166 (34.3%) 305 (33.6%) 0.94 
Other 81 (16.7%) 153 (16.8%) 
None 233 (48.1%) 448 (49.3%) 
Missing 4 (0.8%) 2 (0.2%) 
* p-value from Chi-square test for nominal categories or Cochran-Mantel-Haenszel test for ordered categories. 
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